118237-77-7

Basic information

• Product Name: [(1S,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl]methanol
• Synonyms: (+-)-(1alpha,4alpha)-4-(6-chloro-9H-purin-9-yl)-2-cyclopentenylcarbinol; (+/-)-(1.alpha.,4.alpha.)-4-(6-chloro-9H-purin-9-yl)-2-cyclopentenylcarbinol
• CAS NO: 118237-77-7
• Molecular Formula: C₁₁H₁₁ClN₄O
• Molecular Weight: 250.6842
• Mol File: 118237-77-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 467.3°C at 760 mmHg
• Flash Point: 236.4°C
• Density: 1.6g/cm³
• Vapor Pressure: 1.55E-09mmHg at 25°C
• Refractive Index: 1.761
• CAS DataBase Reference: [(1S,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [(1S,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl]methanol(118237-77-7)
• EPA Substance Registry System: [(1S,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl]methanol(118237-77-7)

Safety Data

• Hazardous Substances Data: 118237-77-7(Hazardous Substances Data)

Usage

General Description

[(1S,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-en-1-yl]methanol, also known as CP-2-101, is a chemical compound with potential antiviral and anticancer properties. It is a purine nucleoside analog that inhibits the replication of RNA viruses, including respiratory syncytial virus and influenza A virus. CP-2-101 has also shown promising anticancer effects by disrupting the proliferation and survival of cancer cells. Additionally, it has been studied for its potential use in treating chronic obstructive pulmonary disease and other inflammatory conditions. Overall, the compound has demonstrated significant potential in the treatment of viral infections and cancer, making it a promising candidate for further research and development in the field of medicine.

Upstream product

• 918492-97-4 (1S,cis)-4-[(5-amino-6-chloro-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol 
• 122-51-0 orthoformic acid triethyl ester 
• 287473-95-4 (1R,cis)-4-[(5-Amino-6-chloro-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol 
• 1233843-29-2 (+)-((1R,4R)-4-(5-amino-6-chloropyrimidin-4-ylamino)cyclopent-2-enyl)methanol 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 79200-56-9 (-)-2-azabicyclo[2.2.1]hept-5-en-3-one 
• 1026978-85-7 N-[(1S,4R)-4-(6-Chloro-purin-9-yl)-cyclopent-2-enecarbonyl]-2-nitro-benzenesulfonamide 
• 153011-43-9 (1S,cis)-tert-butyl N-[4-(hydroxymethyl)-2-cyclopenten-1-yl]carbamate 
• 168960-19-8 (1S,4R)-1-amino-4-hydroxymethyl-2-cyclopentene hydrochloride 
• 168960-19-8 (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene hydrochloride 
• 151792-53-9 tert-butyl (1R,4S)-(-)-3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate 
• 168960-18-7 (1R,4S)-N-(tert-Butyloxycarbonyl)-1-amino-4-(hydroxymethyl)-2-cyclopentene 
• 200002-41-1 (-)-[(1R,4S)-tert-butyl 3-oxo-2-azabicyclo(2.2.1)hept-5-ene-2-carboxylate] 

Downstream Products

• 1233843-34-9 (+)-((1R,4R)-4-(6-chloro-9H-purin-9-yl)cyclopent-2-enyl)methyl-4-methoxy-benzyloxycarbamate 
• 112966-73-1 [(1R,3S)-3-(6-amino-9H-purin-9-yl)cyclopentyl]methanol 
• 220285-03-0 [(1R,3S)-3-(6-amino-9H-purin-9-yl)cyclopentyl]methanol 

Relevant articles and documents

Syntheses of carbocyclic aminonucleosides and (-)-epi-4′-carbocyclic puromycin: application of palladium(0)/indium iodide-allylations and tethered aminohydroxylations

Carbocyclic aminonucleosides and epi-4′-carbocyclic puromycin were prepared from an acylnitroso-derived hetero Diels-Alder cycloadduct. Pd(0)/InI-mediated allylations of a formyl species were used to install the 4′-hydroxymethyl group. A tethered aminohydroxylation strategy was employed to install the cis-2′,3′-aminoalcohol moiety with complete regio- and diastereocontrol.

PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS

The present invention relates to phosphoramidate, and phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1nethanol, processes for their preparation, and their use in treating viral infections.

Antiviral combination comprising nucleoside analogs

Antiviral and antitumor compositions are disclosed comprising a mixture of AZT, ribavirin, d4T or CS-87 with a compound of general formula: STR1 wherein Z is H, OH or NH2, Y is CH, and X is selected from the group consisting of H, N(R)2, SR, OR or halogen, wherein R is H, lower(C1 -C4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable derivatives thereof.